Hidradenitis Suppurativa (HS)GHSHSNCT07659769
Global Healthcare Study on Hidradenitis Suppurativa
An observational study of Hidradenitis Suppurativa (HS) and Hidradenitis Suppurativa (Acne Inversa), run by Julia Tatjana Maul at 1 site in Switzerland.
Trial summary
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with hidradenitis suppurativa. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
- How many people
- 9,600 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2025to 31 Dec 2029
- How long will I take part?
- 5 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patient populations across world regions seen for hidradenitis suppurativa.
Who may be able to join
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Hidradenitis Suppurativa
Who cannot join
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Johannes Didaskalu contact
Switzerland1 site, 1 recruiting
- Recruiting
University of Zurich
Zurich
Julia-Tatjana Maul, Prof. Dr. med., +41 76 441 51 09, julia-tatjana.maul@usz.ch
About this study
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with hidradenitis suppurativa. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Read the detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
- Keywords
- Dermastudy, GHSHS, GHRSD
- Medical subject headings
- Hidradenitis Suppurativa
What is being measured
The primary outcome is the main question the study is designed to answer.
International Hidradenitis Suppurativa Severity Score System (IHS4)
Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Secondary outcomes (6)
Hurley Staging System
Clinician-assessed classification of hidradenitis suppurativa severity categorized as Stage I, Stage II, or Stage III.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Sartorius Hidradenitis Suppurativa Severity Score (HSS)
Clinician-assessed measure of hidradenitis suppurativa severity incorporating lesion counts and anatomical involvement; higher scores indicate more severe disease.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Clinician-assessed global measure of hidradenitis suppurativa severity on a scale from 0 to 4, with higher scores indicating more severe disease.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa
Patient-reported assessment of overall hidradenitis suppurativa severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for pain related to hidradenitis suppurativa
Patient-reported assessment of hidradenitis suppurativa-related pain on a numerical rating scale from 0 (no pain) to 10 (worst imaginable pain).
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start1 Jan 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hidradenitis Suppurativa (HS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 9,600 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Julia Tatjana Maul
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich, University Hospital, Zürich
- Responsible party
- Sponsor-investigator, Julia Tatjana Maul, University of Zurich
- Investigators
- Julia-Tatjana Maul, Prof. Dr. med., Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07659769
- Sponsor's protocol ID
- 2024-01704-3
- Acronym
- GHSHS
- Status last verified
- Sep 2026
- First submitted
- 15 Jun 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No